406 related articles for article (PubMed ID: 11394498)
1. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
2. Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother (1991); 2001 May; 24(3):212-220. PubMed ID: 11395636
[TBL] [Abstract][Full Text] [Related]
3. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
4. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097
[TBL] [Abstract][Full Text] [Related]
5. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Kang X; Kawakami Y; el-Gamil M; Wang R; Sakaguchi K; Yannelli JR; Appella E; Rosenberg SA; Robbins PF
J Immunol; 1995 Aug; 155(3):1343-8. PubMed ID: 7543520
[TBL] [Abstract][Full Text] [Related]
6. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
Kittlesen DJ; Thompson LW; Gulden PH; Skipper JC; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1998 Mar; 160(5):2099-106. PubMed ID: 9498746
[TBL] [Abstract][Full Text] [Related]
7. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
9. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).
Parkhurst MR; Fitzgerald EB; Southwood S; Sette A; Rosenberg SA; Kawakami Y
Cancer Res; 1998 Nov; 58(21):4895-901. PubMed ID: 9809996
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
Valmori D; Pittet MJ; Vonarbourg C; Rimoldi D; Liénard D; Speiser D; Dunbar R; Cerundolo V; Cerottini JC; Romero P
Cancer Res; 1999 Aug; 59(16):4050-5. PubMed ID: 10463606
[TBL] [Abstract][Full Text] [Related]
11. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
Brichard VG; Herman J; Van Pel A; Wildmann C; Gaugler B; Wölfel T; Boon T; Lethé B
Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071
[TBL] [Abstract][Full Text] [Related]
12. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
13. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
14. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
16. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
17. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes.
Wölfel T; Van Pel A; Brichard V; Schneider J; Seliger B; Meyer zum Büschenfelde KH; Boon T
Eur J Immunol; 1994 Mar; 24(3):759-64. PubMed ID: 8125142
[TBL] [Abstract][Full Text] [Related]
18. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
[TBL] [Abstract][Full Text] [Related]
20. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
Slingluff CL; Cox AL; Henderson RA; Hunt DF; Engelhard VH
J Immunol; 1993 Apr; 150(7):2955-63. PubMed ID: 7681084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
